Research and Patents by Malecare

On October 27, 2015, Malecare was issued patent 9,168,002 for a device and method for real time simultaneous measurement of radiation at specific parts of your body. Understanding cumulative radiation exposure in people undergoing ionizing radiation for diagnostics and medical treatment is essential towards reducing secondary tumors from primary radiation therapy.   We believe that the Malecare device will be universally accepted at all radiation treatment facilities, worldwide and will save thousands of lives every year.
All of the following projects have several papers either in production, submitted or accepted for publication in peer reviewed journals.

Molecular Oncology Project
Marketing new tests and diagnostics requires understanding the semiotics of patient appreciation of novel health opportunities.  Our first phase involved accruing 200 prostate cancer patients for a free in-depth molecular oncology testing and consultation, which Malecare conducted in collaboration with Massive Bio.   During phase two, Malecare conducted in-depth interviews with these patients regarding their experience with our molecular oncology testing and consultation. From these interviews, Malecare will discover how to communicate the value of new testing and consultant opportunities to prostate cancer patients.

Facing Cancer Alone
Malecare conducted the first large scale survey (N=1799) to understand what if any benefits are accrued by co-habitation to treatment compliance, quality of life and psycho-social stability for men diagnosed with prostate cancer.  This research will be presented during ASCO-GU January 2016.

My Prostate Cancer Experience
Malecare completed a N=1268 survey of men diagnosed with prostate cancer, exploring their day to day experience managing side effects, their experience specific advanced stage treatments and their relationship with their Doctors, across the continuum of their treatment experience.  This survey also discovers significant disparities in experience across the age of diagnosis, race, gender and sexual identity.

Better Ask
Malecare’s research study (N=622) investigated the quality of the patient-doctor consultation during prostate cancer treatment.  We discovered how patients and doctors ask and respond to questions during their prostate cancer consultation. We also investigated how patients spend their “waiting room” time.

The Restore Study
Funded by the National Cancer Institute at NIH, Malecare in collaboration with the University of Minnesota investigated how prostate cancer treatment affects gay and bisexual men, partners, and family and friends.  The study focused on how different treatments affect sexual functioning, gay sex, and gay relationships. We will use this information to design better sexual rehabilitation interventions for gay and bisexual men.  Completed in November, 2015, we achieved the largest and most comprehensive survey of gay and bisexual men with prostate cancer ever conducted.

Twice As Many
Malecare interviewed men of African Descent diagnosed with prostate cancer and spouses to understand the psycho-social dimensions regarding prostate cancer killing African American men at 2.4 times the rate as it kills Caucasian men.   Malecare developed new methods of messaging to African American men diagnosed with prostate cancer and dispelled several myths about African American men and clinical trial accrual.

Using Social Media
Malecare surveyed 634 men diagnosed with prostate cancer to understand how they use and value information derived from social media.